ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yoh Watanabe
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kara, M.
Right arrow Articles by Watanabe, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kara, M.
Right arrow Articles by Watanabe, Y.
Related Collections
Right arrow Lung - cancer
Right arrow Molecular biology

Ann Thorac Surg 2001;71:944-948
© 2001 The Society of Thoracic Surgeons

Original article: general thoracic

Autocrine motility factor receptor expression in patients with stage I non–small cell lung cancer

Murat Kara, MDa, Yasuhiko Ohta, MDa, Yoko Tanaka, PhDa, Makoto Oda, MDa, Yoh Watanabe, MDa

a First Department of Surgery, Kanazawa University School of Medicine, Kanazawa, Japan

Accepted for publication May 9, 2000.

Address reprint requests to Dr Kara, Guvenlik caddesi, Esenlik sokak 7/10, Asagiayranci, Ankara 06540, Turkey
e-mail: muratkara66{at}hotmail.com

Background. Expression of autocrine motility factor receptor (AMFR) associates with increased cell migration and poor survival in certain types of human cancers. We assessed the possible correlation between AMFR, clinicopathologic features, and survival in stage I non–small cell lung cancer (NSCLC).

Methods. AMFR expression was analyzed immunohistochemically, using a monoclonal antibody (3F3A) in tumor specimens from 97 patients with curative resection. Vascular endothelial growth factor (VEGF) expression was also examined after accounting for AMFR expression.

Results. Out of 97 tumors, 38 (39.2%) were positively stained with AMFR. The AMFR expression was significantly associated with histologic type of tumor, mainly in adenocarcinoma. Overall survival of patients with AMFR-positive tumors was significantly worse than that of AMFR-negative tumors (p = 0.0050). The AMFR expression appears to be associated with VEGF expression. Patients who were AMFR positive and had high VEGF expression had a worse prognosis compared with the AMFR-negative and low VEGF-expression group (p < 0.0001). Multivariate analysis revealed an independent prognostic impact of AMFR on survival (p = 0.0039).

Conclusions. These results indicate that evaluation of AMFR expression may provide useful guidance in follow-up of patients with NSCLC.




This article has been cited by other articles:


Home page
 ChestHome page
M. D. Brundage, D. Davies, and W. J. Mackillop
Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress
Chest, September 1, 2002; 122(3): 1037 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. Kara, E. Dikmen, D. Kilic, S. Dizbay Sak, D. Orhan, S. K. Kose, and S. Kavukcu
Prognostic implications of microscopic proximal bronchial extension in non-small cell lung cancer
Ann. Thorac. Surg., August 1, 2002; 74(2): 348 - 354.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The Society of Thoracic Surgeons.